SID1 transmembrane family member 1Genealiases: SID-1 · SID1
Q-omics provides the consensus-scored SIDT1 profile across patient tissues and cancer cell-line models. SIDT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SIDT1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, SIDT1 RNA expression shows 26,147 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRP, and LSCC as cancer lineages where SIDT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIDT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIDT1 survival associations across molecular data types. SIDT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIDT1 RNA expression–survival associations across cancer types. High SIDT1 expression shows favorable associations in HNSC, BLCA, SKCM, LIHC, KICH and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SIDT1 RNA expression.
This table summarizes SIDT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SIDT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIDT1 shows lower tumor expression in KIRP, COAD, KIRC and LUSC and higher tumor expression in BRCA and LUAD. The KIRP box plot shows higher SIDT1 RNA expression in normal versus tumor tissue (log2 FC = −0.763, t-test p < 0.001).
This table shows molecular features associated with SIDT1 in patient tissues and cancer cell lines. In patient samples, SIDT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIDT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
